Planning a cancer-care visit to China

First establish whether the visit is for an opinion, treatment assessment or research assessment. Then list the records, proposed dates and follow-up responsibilities.

Start here

  • Ask both clinical teams which records and images the receiving team needs.
  • Put assessment, possible treatment, reviews and follow-up on separate calendar lines; mark unconfirmed dates.
  • For a trial, ask the study team for its identifier, exact site and current recruitment status.
  • Confirm which clinician will explain results and oversee care after you return.

Start with the purpose of this visit

Ask the receiving team whether the first visit is for a second opinion, an assessment for treatment or an assessment for a research study. Keep the precise treatment or study name in your notes. Ask what can be reviewed from existing records and what needs an in-person assessment.

The US National Cancer Institute describes a second opinion as another specialist reviewing the case materials. That opinion may agree with the original plan or suggest a change. Ask how the written opinion will be shared with your current treating clinician.

Agree on the records before translating them

NCI advises involving the current doctor in obtaining a second opinion so that records, including test results and images, can reach the reviewing doctor. Ask both teams which existing documents they need, including whether a treatment summary, pathology reports or original image files are relevant.

Make a list of those requested items, their dates and languages. Flag anything missing. Confirm the receiving team's format and translation requirements before commissioning work, and keep originals with translations. Record sharing needs an approved private process; ordinary public enquiry forms are not a place for medical records.

Put the whole proposed sequence on a calendar

Ask about assessment, treatment appointments, interim reviews and follow-up as separate entries. NCI explains that chemotherapy schedules vary and may include cycles of treatment followed by rest. This is one example of why the length of a cancer-care trip may remain uncertain after the first appointment.

Which dates are confirmed? Which depend on the clinical assessment or later decisions? Ask whether you would need to remain nearby or return for another visit. Leave decisions about treatment timing and travel suitability with the clinical team, and check the change terms of accommodation and transport separately.

Clarify approved care and clinical research

For any claim that a treatment is approved, ask which country, product and intended use the approval covers. Ask the provider to explain the status of the specific care being proposed in China. This guide has not verified an approval or access route for any treatment.

For a clinical trial, ask for the study identifier and exact site. NCI explains that trials can test new treatments or new ways of using existing treatments; each follows a protocol with its own visit and procedure schedule. Ask the study team about current recruitment, assessment, costs and follow-up requirements for someone living overseas. A registry entry leaves those practical questions unresolved.

Identify who takes responsibility after you leave

Ask which clinician will review pending results, explain changes and oversee care after your return. Check that the proposed clinician at home has agreed to that role. Ask what information they need from the receiving team and who will supply it.

For people whose cancer treatment has ended, NCI recommends a treatment summary and follow-up care plan. If your visit is only one stage of ongoing care, ask what written account and instructions apply to that stage. Confirm when these documents will be ready, their language and who will explain them.

Before you go

Ask the clinical team to review a one-page list of requested records, proposed appointments and the clinician responsible after each stage. Mark every unconfirmed item.

General administrative information, not treatment advice. US educational sources do not establish Chinese approval, trial eligibility, live availability, overseas follow-up or a suitable trip length.

Official sources